Brelovitug (BJT-778) Clinical Trials

1 actively recruiting trial

Also known as: BJT-778

Pipeline

Phase 2/3: 1

Top Sponsors

Mirum Pharmaceuticals, Inc.1

Indications

Chronic Hepatitis D1
Liver Disease1

Other1 trial

Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.